Form 4: VolitionRx CMO's Tax Withholding on RSU Vesting

VolitionRx's Chief Medical Officer, Andrew Retter, had shares withheld for tax obligations related to the vesting of restricted stock units.

Summary

• Andrew Retter, Chief Medical Officer of VolitionRx Ltd (VNRX), reported a transaction on November 1, 2025.
• The transaction involved the disposition of 4,588 shares of common stock at a price of $0.434 per share.
• These shares were retained by VolitionRx for cancellation to satisfy tax withholding obligations upon the settlement of 9,762 restricted stock units (RSUs).
• The RSUs were awarded in lieu of cash compensation that would otherwise have been owed to Mr. Retter.
• No shares were sold by Mr. Retter or VolitionRx in this transaction.
• Following this transaction, Mr. Retter beneficially owns 146,568 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to executive compensation and tax withholding, which is a neutral event for the company's operational or financial performance.

Positives

• The vesting of 9,762 restricted stock units represents a form of compensation for the Chief Medical Officer, indicating continued executive incentive alignment.

Negatives

• No direct negatives for the company or investors are indicated by this routine tax withholding event.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "No shares were sold by the reporting person or VolitionRx in such transaction."

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, common across all industries for publicly traded companies that grant equity awards like restricted stock units.

Comparison to Industry Standards

• The practice of withholding shares to cover tax liabilities upon the vesting of restricted stock units is a standard and widely accepted method of managing executive equity compensation in public companies, aligning with common corporate governance and tax compliance practices across the U.S. market.
• This transaction is consistent with how companies like Pfizer, Johnson & Johnson, or other biotech firms handle RSU vesting for their executives, where a portion of the vested shares is typically withheld to satisfy statutory tax obligations.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine compensation-related event and does not reflect operational changes or significant shifts in insider holdings.
• Employees: No direct impact beyond the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding event for an executive's restricted stock units. It provides no new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as there are no fundamental catalysts or deterrents presented in this filing.

Keywords

VNRX, VolitionRx, Form 4, insider transaction, RSU, restricted stock units, tax withholding, Andrew Retter, executive compensation